FDA

Europe's struggling economies may have unexpected effects on the pharmaceutical sector.

FDA wants sponsors to build quality into protocols, adopt risk-based strategies to streamline trials.

A British Medical Journal survey suggests that misconduct in research is not going away.

Pressure to approve new user fees will affect policies for foreign studies and research methods.

While risk and uncertainty remain high, the pace of innovation will remain glacial.

The importance of safe use of imaging agents was highlighted at the Chicago Radiological Society of North America conference.

Patricia Brunko addresses the decline in European clinical trials, but still gives the industry hope.

The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.

A comprehensive listing of US departments and offices that includes the telephone numbers of directors, commissioners, and advisors.

The Innovative Medicines Initative has launched several projects to improve quality of life.

Alternative approaches aim to tackle drug shortages, spur orphan drug development.

Multiple regulatory and reimbursement proposals are slated to expand legislation to renew PDUFA.

EU's new rules will be influenced by more than just those primarily responsible for pharmaceuticals.

Modernizing the Common Rule to update research policies could spell important changes.

While order might be useful for smaller firms to do business, it is not useful in helping them to innovate.

Open Facebook walls could bombard companies with AERs.

EU's new rules will be influenced by more than just those primarily responsible for pharmaceuticals.

A meeting in July to discuss changes to the old rules explored the need for compromise across the industry.

Pharmaceutical testing and production overseas spurs call for more reliance on counterparts.

Partnership formation is the new trend in common technical document development.

A newly released report has the pharma industry facing some new rivals.

Debate narrows over extent of pre-clinical and clinical testing for follow-on versions of complex biologics.

Potential patients entering any trial need to be informed citizens able to understand and assert their rights.

A potential solution for many, personalized medicine still faces economic, regulatory, and cultural challenges.

CER funding boosts agency informatics initiatives that promise to modernize research and review processes